Objective. To identify possible imbalance of tumour necrosis factor alpha (TNFa) and its soluble receptors in the different subgroups of juvenile chronic arthritis (JCA).
Juvenile chronic arthritis (JCA) refers to a group of subgroups with respect to individual joints. The juvenile spondyloarthropathies are members of a different clinical idiopathic arthritides of childhood. Although arthritis is group. Although the laboratory markers of inflammation the salient feature of all these diseases, there are importcan be impressive, the natural history of juvenile ant clinical differences which suggest that the underlying spondyloarthropathies is towards new bone formation, pathology may be different.
fibrosis and ankylosis rather than bone resorption [6] [7] [8] . Pauciarticular JCA, involving four or fewer joints [1] , This would suggest that different mechanisms of inflamusually runs a benign course. While clinically quite mation and/or repair occur in the subgroups of JCA. marked inflammation can be observed in individual joints,
The inflammatory cytokines have long been implicdestruction of that joint is an uncommon finding long ated in the pathogenesis of inflammation and in particuterm [2, 3] . In contrast, polyarticular disease is frequently lar arthritis [9] [10] [11] [12] . Tumour necrosis factor alpha associated with joint damage and erosive changes [4, 5] .
( TNFa) exhibits many biological actions both in vitro While serological indices of inflammation are more freand in vivo pertinent to arthritis. It can induce an quently raised in polyarticular disease, there is little to inflammatory response, collagenase production [13, 14] , distinguish between the clinical findings of these two bone and cartilage resorption [15, 16 ] and cachexia [17] . TNFa is one of the primary stimulants of interleukin-1 that TNFa plays a central role in the cytokine network nique. Samples were immediately spun and stored at −70°C until assayed. in rheumatoid arthritis as well as cellular immunity.
Blood samples were available on 31 children. CRP The cytokine network is essential to host defence and was measured by nephelometry and ESR using the thus regulatory mechanisms are essential for homeostWestergren method. Serum samples were spun and asis [20, 21] . Several mechanisms are currently known rapidly frozen at −70°C until used. to down-regulate the pro-inflammatory cytokines includEthical Committee approval was obtained for this ing anti-inflammatory cytokines [22, 23] and cytokine study at Great Ormond Street Hospital National Health antagonists, which are present in synovial fluids [24, Service Trust and patient assent and parent consent 25]. TNFa binds to two high affinity cell surface recepgiven. tors, TNFRI and TNFRII, which are present on virtually all cell types [26, 27] . The extracellular domains of Cytokine determination these receptors exist in a soluble form and have been TNFa determination in synovial fluid and serum. shown to bind circulating TNFa and thus inhibit its Synovial fluid and serum samples were initially assayed biological activity [28] . Among the factors which may for TNFa by EASIA (Medgenix, Fleurus, Belgium) with influence cellular responses induced by TNFa are the a limit of sensitivity of 20 pg/ml. In 60% of samples number of cell-associated receptors and the concentraassayed, TNFa levels were below the limit of detection tion of soluble TNFRI and TNFRII receptors in the of the assay. These negative samples were subsequently extracellular fluid.
reassayed using a high sensitivity enzyme-linked immuThe relative proportion of TNFa to its soluble recepnosorbent assay ( ELISA) (R & D Systems Europe, tors in biological fluids has proved to be important in a Abingdon, Oxon) with a limit of sensitivity of 2 pg/ml. number of clinical conditions [29] [30] [31] [32] . In meningococcal Both assays were chosen as their antibodies detected septicaemia, a diminished ratio of soluble TNFRI and both free and complexed TNFa (as confirmed by the TNFRII to TNFa was observed in those patients with manufacturers). Intra-assay variation was 11.7% with a fatal outcome compared with survivors [30] .
an interassay variation of less than 10% for the indiWe postulated, therefore, that levels of TNFa and its vidual assays used. There was a tendency for the high soluble receptors might be different in the synovial fluid sensitivity kit to give lower values to high TNF levels of the various subgroups of JCA thus reflecting their than observed using the low sensitivity kit. This was contrasting clinical courses.
probably due to the fact that the TNFa antibodies used in these kits are directed against different TNFa epitopes, the different standards used for the calibration curves, were assayed by ELISA (R & D Systems Europe). Both The degree of joint inflammation observed clinically was inter-and intra-assay variation was less than 10% for scored on a scale of 1-3 indicating mild, moderate or each individual system used. Using values from the marked synovitis, by the same observer. Three children initial in-house assay for sTNFRI as internal controls, had systemic JCA and due to their small numbers were we observed that values on the same samples from the excluded from the study. Two children, one from the R & D System Method were consistently twice as high polyarticular group and one from the pauciarticular as the original results, and thus R & D readings were group had synovial fluid TNFRII and RII/TNFa ratios halved in order to be able to combine results from 10 times higher than the maximum ratios observed in samples measured only with the R & D kit and those either group and were excluded as these results were measured by both methods. probably incorrect, and a re-test was not possible due Statistical analysis to the small number of samples available. Thus, 45 children completed the study in which 47 knees were Since specimens were available in limited amounts only aspirated. There were 25 in the pauciarticular group, 13 it was not possible to test them by both assays. As in the polyarticular group and seven with a spondylosynovial fluid values for the TNFa and TNFRI and arthropathy. Values for erythrocyte sedimentation rate TNFRII were obtained by different assays, non-( ESR) and C-reactive protein (CRP) were available on parametric analysis by the Kruskal-Wallis one-way ana-12 pauciarticular, seven polyarticular and four patients lysis of variance was used to compare the three clinical with spondyloarthropathy and the clinical details and subgroups. Subsequently the Mann-Whitney U-test was results are included in Table 1. used to compare each pair of group medians. For analysis of TNFa values using the low sensitivity kit, Synovial fluid was aspirated using an aseptic tech- samples below the limit of detection were given a value than the median of the other two groups, this was not of 20 pg. For analysis of results obtained using the high significant. sensitivity kit, values were censored at 33 pg, the highest In 16 patients sTNFRI and II were measured. All value observed using this assay. The Bonferroni correcsamples were measured by the same assay system [27] tion was used to adjust the P values obtained from the as were the synovial fluid samples used for comparison. Mann-Whitney U-tests to take into account multiple For all patients the mean serum sTNFRI was 1.25 comparisons.
(range 0.6-2.1 ng/ml ). The level of serum sTNFRII was All serum samples were assayed by the same assay for twice that of sTNFRI, mean 3.5 (range 2.3-6.0 ng/ml ) TNFa, sTNFRI and sTNFRII and values were found P = 0.001. Insufficient serum samples were available for to be normally distributed if log transformed using analysis of sTNFRs within the disease subgroups. Shapiro and Francia's W-test. However, the assumption Synovial fluid TNFa levels were compared in the of constant variances were not valid. Therefore, the three subgroups and the results obtained using both the results were expressed as medians and analysed by the low and high sensitivity assays are shown in Fig. 2a, b . Kruskal-Wallis one-way analysis of variance.
Using the low sensitivity assay, TNFa levels were higher in the polyarticular group [median 64, 95% confidence interval (CI ) <20-136 pg/ml ] when comResults pared with the pauciarticular group (median <20, 95% Thirty-three serum samples were assayed for TNFa and CI < 20-36 pg/ml ) but not significantly so, P = 0.12 all samples were assayed by the high sensitivity kit from ( Fig. 2a) . The lowest levels of TNFa were observed in 17 pauciarticular JCA, 10 polyarticular JCA and six those children with spondyloarthropathy (median <20, spondyloarthropathy patients (Fig. 1) . Although the 95% CI < 20-20 pg/ml ) which were significantly lower median value for the polyarticular group appears higher than the polyarticular group, P = 0.02, but not the pauciarticular group, P = 0.16. Using the high sensitivity assay, TNFa levels were again highest in the polyarticular group (median >33, 95% CI 18 to >33 pg/ml ) (Fig. 2b) . Intermediate values were observed in the pauciarticular group (median 30.4, 95% CI 13.5 to >33 pg/ml ), which were not significantly different than the polyarticular group, P = 0.3. The lowest levels were observed in the spondyloarthropathy group (median 9, 95% CI 5.9-18.6 pg/ml ), which were significantly lower than both the pauci-and polyarticular groups, P = 0.01 and P = 0.002, respectively.
Significantly higher levels of sTNFRI were observed in the synovial fluid of the polyarticular group than in the pauciarticular group (median 9.2, 95% CI 7.3-11.4 pg/ml vs median 6.3, 95% CI 5.6-7.5 pg/ml ) F. 1. Serum TNFa levels within the three clinical subgroups. Horizontal bars indicate median values. P = 0.004 (Fig. 3a) . Levels were intermediate in the TNFa were taken to be 51. Values obtained using the high sensitivity assay were used. The molecular weights spondyloarthropathy group but were not significantly different from the other two groups (P = 0.4 and of sTNFRI and sTNFRII were taken to be 55 kDa and 75 kDa respectively, and molar concentrations of TNFa P = 1.0, respectively).
As with sTNFRI, significantly higher sTNFRII levels and its receptors calculated accordingly. The results are displayed in Fig. 4a -c. The TNFRI/TNFa ratio was were observed in the polyarticular group when compared with the pauciarticular group (median 12.8, 95% CI much higher in the spondyloarthropathy group (median 815, 95% CI 581-1447) than in the pauci-and polyartic-11.5-17.9 pg/ml vs median 9.7, 95% CI 7.4-12.1 pg/ml ) P = 0.03 (Fig. 3b) . Again there was no significant ular groups (median 286, 95% CI 224-468; P = 0.003 and median 353, 95% CI 257-447; P = 0.003; respectdifference between the subset with spondyloarthropathy (median 8.0, 95% CI 2.0-14.5 pg/ml ) and the other two ively). There were no significant differences between the polyarticular and pauciarticular groups P = 1.0 groups (P = 0.11 and P = 1.0, respectively). Analysis of 16 paired serum and synovial fluid samples revealed ( Fig. 4a) . A similar trend was observed in the TNFRII/ TNFa ratios, with the highest ratios being observed in sTNFRII to be almost eight times higher than serum sTNFRI: mean 9.1 (range 5.0-16.0 ng/ml ) vs mean 1.25 the spondyloarthropathy group (median 980, 95% CI 367-2837), which was greater than that observed in the (range 0.6-2.1 ng/ml ) P = 0.001. sTNFRII levels were four times higher in synovial fluid than in serum: mean polyarticular group (median 793, 95% CI 554-980) and the pauciarticular group (median 535, 95% CI 392-688). 13.7 (range 7.8-28.9 ng/ml ) vs mean 3.5 (range 2.3-6.0 ng/ml ) P = 0.001.
However, the differences were not statistically significant, P = 0.9 and P = 0.3 (Fig. 4b ). Since the biological activity of TNFa appears to be related to the ratio of TNFa to its soluble receptors in Finally, the soluble receptor levels were combined to represent total TNFa inhibitory function and expressed vivo, these were calculated for the synovial fluid samples using the results of the high sensitivity assay. Molar as a ratio to TNFa (Fig. 4c) . As expected, the highest ratios were observed in the spondyloarthropathy group ratios were calculated taking the molecular weight of TNFa to be 17 kDa. Since TNFa circulates in a trimolec-(median 1556, 95% CI 1052-4285), which was significantly higher than the pauciarticular group (median 835, ular complex, apparent molecular weight values for statistically significant, P = 0.11. Clinically mild, moderate and marked degrees of inflammation were equally divided between the three disease subgroups ( Fisher's exact test P = 0.36).
Discussion
A number of clinical findings differentiate JCA from adult rheumatoid arthritis. In all forms of JCA erosive change is much less commonly seen. On the contrary, new bone formation leading to ankylosis is a frequent occurrence particularly in the spondyloarthropathies [7] . In pauciarticular disease, even with recurrent episodes of inflammation within a given joint, neither erosion nor new bone formation is common, particularly in early disease [4] . In adult rheumatoid arthritis the inflammatory cytokines have been implicated in the observed erosive disease. TNF is widely expressed and detected in the tissues and fluid of the synovial joint, and has been shown to induce collagenase production [13] and to resorb both cartilage and bone both in vivo and in vitro [15, 16 ] . We and others have shown that the inflammatory cytokines are involved in the different subgroups of JCA [12, 33- In recent years there has been increasing interest in the role of the soluble TNF receptors in a variety of diseases [30] [31] [32] . Girardin et al. [30] noted that in children with severe meningococcal septicaemia, levels of sTNFRI and sTNFRII initially increased as TNF increased. However, at TNFa levels greater than 500 ng/ml no further increase in the soluble receptors TNF receptors protect against the TNF-mediated effects observed in septic shock. 95% CI 720-1071) P = 0.01. Similarly there was a The clinical situation is somewhat different in JCA significant difference in the RI+RII/TNFa ratio when compared with acute septic episodes. First, serum between the spondyloarthropathy and polyarticular TNFa levels are either low or undetectable and certainly groups, the latter having a median of 1133 (95% CI never reach the levels observed in septic shock. However, 817-1418) P = 0.05. in our study synovial fluid levels in the 100 pg/ml range Synovial fluid levels of TNFa were compared accordwere not unusual and unlike acute septic episodes may ing to the clinical severity of joint inflammation (data remain elevated for months or years while synovitis not shown). While there was a trend to higher levels in patients with moderate disease activity, this was not persists.
In contrast to our findings, Madson et al. [36 ] plete loss of TNFa bioactivity, as little as 30 molar excess of the soluble receptors can have some inhibitory observed increases in a number of inflammatory cytokines but not TNFa in both the serum and synovial activity [31] . In our study, sTNFRs were present in between 100 and 5000-fold molar excess, thus it is fluid in JCA. The explanation for this discrepancy may be a technical one, in that a number of anti-TNF conceivable that there would be considerable differences in the bioactivity of TNFa in synovial fluid with low antibodies used in assays do not detect complexed TNFa, its predominant form in biological fluids [37] .
and high sTNFR levels. Since significantly lower ratios were observed in the polyarticular group (on average Cope et al. [24] and Roux-Lombard et al. [25] observed increased levels of both TNFa and its soluble receptors 180 molar excess) when compared with the spondyloarthropathy group (molar excess 770), it could be in the synovial fluid of patients with rheumatoid arthritis and that sTNFRs were four to five fold higher in anticipated that the resorptive effects of TNFa on bone and cartilage within the joint in the former group would synovial fluid than in serum levels. These results concur with our own where synovial fluid sTNFRs were on be expected to be more marked when compared with the latter. This would provide at least part of the average six times greater than serum levels. Furthermore, as they observed, synovial fluid sTNFRII levels were on explanation for the different clinical courses of these disease subgroups. It could be argued that diseaseaverage 1.5 times higher than TNFRI. Interestingly, in our patients with JCA serum sTNFRII was twice as modifying and anti-inflammatory agents such as methotrexate, sulphasalazine and steroids might in themselves high as sTNFRI. This contrasts with the findings in sepsis where sTNFRII levels are at least three to four alter cytokine and receptor concentrations. These drugs were taken by approximately 50% of both the spondytimes higher than sTNFRI. These variations in the ratios of the sTNFRs in different disease states and loarthropathy and polyarticular groups: 3/7 children with spondyloarthropathies were given sulphasalazine biological fluids may be due to the different standards used in the individual assays employed. Alternatively, compound, and 6/13 children with polyarticular JCA were treated with methotrexate. they may reflect the different mechanisms of shedding of the two receptors, in particular variations in responsIn conclusion we have observed a significant difference in the levels of TNFa and the sTNFRs TNFa ratios in iveness of TNFRI and TNFRII to TNFa stimulation [38] , or the effect of proteolytic enzymes, particularly the different subgroups of JCA. Whilst recognizing that TNF is only one of the many cytokines, not to mention elastase or other metalloproteinases, known to be present in inflamed joints [39] . Furthermore, the cell popugrowth factors, involved, and this system of agonist/ antagonist is only one of many methods of regulation lations within the joint are quite distinct from those observed in the peripheral blood. Thus, the observed which might influence bone destruction and remodelling in JCA, these findings reflect different pathophysiologies sTNFRI and RII levels may reflect different receptor expression known to occur on different cell types at play within the different subgroups of JCA, in particular, juvenile spondyloarthropathy. [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] . Since the vast majority of synovial fluid cells are neutrophils it is surprising that TNFRII, the most abundant polymorphonuclear leukocytes TNFR, is not
